Table 4: Analysis of serum lipid level.

Serum lipid level (comparison)Intervention groupControl groupWeight (%) MD 95% CI
MeanSDMeanSD

(1) TC (mmol/L)
(1.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 5.41 0.87 6.54 0.89 11.40 −1.13
Huang et al. 2009 [24] 4.98 0.79 5.99 0.87 13.30 −1.01
Ma and Teng 2005 [29] 9.00
Wang et al. 2004 [6] 4.33 0.96 0.79 11.10 −1.97
Xu 2005 [39] 5.49 1.12 0.93 6.60 −0.71
Yan 2006 [34] 17.30
Yan and Li 2007 [33] 0.13 5.93 0.23 17.00 −1.03
Zhou et al. 2003 [38] 0.54 4.84 0.78 14.30 −0.54
Overall (REM, I2 = 92%)100
(1.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 4.65 0.67 5.22 0.88 −0.57
Yu et al. 2002 [35] 0.58 6.72 0.85 −2.62
(1.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(1.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 4.57 1.42 5.32 1.72 9.5 −0.75
(1.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 4.62 0.63 4.36 13.8 0.26
Jiang and Cai 2001 [25] 5.19 4.91 0.66 12.8 0.28
Lou et al. 2008 [28] 5.4 0.12 0.11 14.4
SubgroupOverall (REM, I2 = 69%)
(1.3.3) Xuezhikang and conventional therapy versus fluvastatin and conventional therapy
Gao and Liao 2003 [21] 4.05 0.74 3.63 0.59 13.1 0.42
(1.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 4.65 0.79 4.88 0.85 13.5 −0.23
Xu 2005 [39] 5.49 1.12 0.92 8.8 −0.01
Zhang 2011 [37] 4.51 0.38 3.35 14.1 1.16
SubgroupOverall (REM, I2 = 97%)
After sensitive analysisSubgroupOverall (FEM, I2 = 0%)
TotalOverall (REM, I2 = 96%)
After sensitive analysisTotalOverall (REM, I2 = 66%)
(1.4) Xuezhikang and statin and conventional therapy versus statin and conventional therapy
(1.4.1) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27] 0.71 0.81 35.6
(1.4.2) Xuezhikang and fluvastatin and conventional therapy versus fluvastatin and conventional therapy
Zhang 2010 [36] 0.24 64.4
TotalOverall (REM, I2 = 68%)
(1.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32] −1.05
2. TG (mmol/L)
(2.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 1.84 0.68 0.87 5.50 −0.48
Huang et al. 2009 [24] 1.49 0.31 1.97 0.37 44.40 −0.48
Ma and Teng 2005 [29] 10.50
Wang et al. 2004 [6] 1.88 0.5 2.2 0.76 7.70 −0.32
Xu 2005 [39] 0.92 2.52 1.67 0.90 0.18
Yan and Li 2007 [33] 1.54 2.02 0.59 19.10 −0.48
Zhou et al. 2003 [38] 0.66 0.61 12.10
Overall (FEM, I2 = 0%)100%
(2.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 1.58 0.78 1.75 0.88 50.80 −0.17
Yu et al. 2002 [35] 2.22 0.71 3.51 0.36 49.20 −1.29
(2.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(2.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 3.75 1.17 3.82 1.29 1.3 −0.07
(2.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 1.85 0.81 1.92 0.72 5.5 −0.07
Jiang and Cai 2001 [25] 1.9 0.72 2.11 0.91 3.5 −0.21
Lou et al. 2008 [28] 3.1 0.2 3.2 0.33 35.2
SubgroupOverall (FEM, I2 = 0%)
(2.3.3) Xuezhikang and conventional therapy versus fluvastatin and conventional therapy
Gao and Liao 2003 [21] 1.01 0.63 1.42 0.46 6.2 −0.41
(2.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 1.61 0.53 1.57 0.55 14.1 0.04
Xu 2005 [39] 2.7 0.92 2.22 0.73 1.0 0.48
Zhang 2011 [37] 1.64 0.33 1.61 0.21 33.0 0.03
SubgroupOverall (FEM, I2 = 0%)
TotalOverall (FEM, I2 = 45%)
(2.4) Xuezhikang and statin and conventional therapy versus statin and conventional therapy
Zhang 2010 [36] 1.58 1.85 −0.27
(2.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32]
(3) LDL-C (mmol/L)
(3.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 3.42 0.96 3.93 0.81 13.50 −0.51
Huang et al. 2009 [24] 2.88 0.91 3.96 0.96 14.10 −1.08
Wang et al. 2004 [6] 2.21 0.4 3.87 0.56 15.20 −1.66
Xu 2005 [39] 2.82 0.95 3.7 0.95 10.50 −0.88
Yan 2006 [34] 2.89 0.44 2.9 0.6 15.50 −0.01
Yan and Li 2007 [33] 2.97 3.88 16.20 −0.91
Zhou et al. 2003 [38] 3.22 0.6 3.68 0.71 15.00 −0.46
Overall (REM, I2 = 94%)
(3.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 2.66 0.85 3.23 0.85 50.30 −0.57
Yu et al. 2002 [35] 2.48 0.39 0.39 49.70 −1.82
(3.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(3.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 2.45 0.72 3.25 0.84 10.6
(3.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 2.68 0.55 2.52 0.49 13.9 0.16
Jiang and Cai 2001 [25] 3.1 0.41 12.2
Lou et al. 2008 [28] 2.8 0.09 2.9 0.1 15.7
SubtotalOverall (REM, I2 = 79%)
(3.3.3) Xuezhikang and conventional therapy versus fluvastatin and conventional therapy
Gao and Liao 2003 [21] 2.13 0.58 2.08 0.61 12.2 0.05
(3.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 2.54 0.56 2.44 0.52 14.2
Xu 2005 [39] 2.82 0.95 2.93 0.52 6.9 −0.11
Zhang 2011 [37] 3.04 0.48 2.51 0.32 14.3 0.53
SubtotalOverall (REM, = 84%)
After sensitive analysisSubtotalOverall (FEM, = 0%)
TotalOverall (REM, = 90%)
After sensitive analysisTotalOverall (REM, = 64%)
(3.4) Xuezhikang and statin and conventional therapy versus statin and conventional therapy
(3.4.1) Xuezhikang and simvastatin and conventional therapy versus simvastatin and conventional therapy
Lin et al. 2009 [27] 0.78 8.4
(3.4.2) Xuezhikang and fluvastatin and conventional therapy versus fluvastatin and conventional therapy
Zhang 2010 [36] 2.87 0.32 91.6 −0.43
TotalOverall (FEM, = 0%)
(3.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32] 100 −0.88
(4) HDL-C (mmol/L)
(4.1) Xuezhikang and conventional therapy versus conventional therapy
Dai et al. 1999 [5] 1.71 0.42 1.04 0.49 14.60 0.67
Huang et al. 2009 [24] 1.12 0.3 0.82 0.2 19.50 0.3
Wang et al. 2004 [6] 1.44 0.38 1.31 0.27 17.00 0.13
Xu 2005 [39] 1.67 0.51 1.68 0.75 7.10 −0.01
Yan 2006 [34] 1.04 1.04 20.60
Yan and Li 2007 [33] 1.09 0.09 0.07 21.10 0.29
Overall (REM, = 93%)
(4.2) Xuezhikang and conventional therapy versus placebo and conventional therapy
CCSPS 2005 [4] 1.24 0.31 1.19 0.31 50.80 0.05
Yu et al. 2002 [35] 1.45 0.25 0.97 0.19 49.20 0.48
(4.3) Xuezhikang and conventional therapy versus statin and conventional therapy
(4.3.1) Xuezhikang and conventional therapy versus lovastatin and conventional therapy
Li et al. 2011 [26] 1.12 0.38 1.06 0.36 11.4 0.16
(4.3.2) Xuezhikang and conventional therapy versus simvastatin and conventional therapy
Huang et al. 2005 [23] 1.85 0.81 1.92 0.72 6.4 −0.09
Jiang and Cai 2001 [25] 1.16 0.17 1.21 0.12 19.0 −0.05
Lou et al. 2008 [28] 0.8 0.03 0.9 0.03 21.4
Overall (FEM, = 0%)
(4.3.3) Xuezhikang and conventional therapy versus fluvastatin and conventional therapy
Gao and Liao 2003 [21] 1.14 0.27 0.45 11 −0.16
(4.3.4) Xuezhikang and conventional therapy versus atorvastatin and conventional therapy
Shang 2007 [31] 1.45 0.41 1.44 0.33 14.9 0.01
Xu 2005 [39] 1.67 0.51 1.53 0.48 3.8 0.14
Zhang 2011 [37] 1.09 0.48 1.62 0.27 12.1 −0.53
SubtotalOverall (REM, = 93%)
After sensitive analysisSubtotalOverall (FEM, I2 = 0%)
TotalOverall (REM, I2 = 79%)
After sensitive analysisTotalOverall (FEM, I2 = 35%)
(4.4) Xuezhikang and fluvastatin and conventional therapy versus fluvastatin and conventional therapy
Zhang 2010 [36] 0.97 0.28 0.82 0.06 100 0.15
(4.5) Xuezhikang and aspirin versus inositol nicotinate and aspirin
Wang and Xiao 2000 [32] 0.95 0.22 0.91 0.25 100 0.17

Note: FEM: fixed effects model; REM: random effects model.